Novel Neuroprotective Drug Shows Promise for Stroke Recovery

Preliminary results from a Phase III clinical trial suggest loberamisal can significantly improve functional outcomes for stroke patients.

Published on Feb. 7, 2026

Got story updates? Submit your updates here. ›

A novel neuroprotective medication called loberamisal is offering hope for stroke patients. Preliminary results from a Phase III clinical trial presented at the American Stroke Association's International Stroke Conference 2026 in New Orleans indicate that early intervention with loberamisal can significantly improve functional recovery in patients with moderate to severe strokes. The trial, conducted across 32 centers in China, found that 69% of patients treated with loberamisal demonstrated excellent functional recovery, compared to 56% in the placebo group.

Why it matters

For years, the focus of stroke treatment has been on physically removing blockages, but even with successful restoration of blood flow, over half of stroke survivors still don't fully recover. Neuroprotective agents like loberamisal aim to preserve the function of brain cells, minimizing the damage caused by the initial stroke and potentially leading to important advancements in reducing or preventing disability after a stroke.

The details

The trial involved 998 adults with moderate to severe strokes caused by blocked vessels. Participants received either a 10-day course of intravenous loberamisal or a placebo, starting within 48 hours of symptom onset. The medication appeared safe, with no increased risk of serious side effects or death compared to the placebo.

  • The trial was presented at the American Stroke Association's International Stroke Conference 2026 in New Orleans.
  • The trial was conducted across 32 centers in China.

The players

Shuya Li, M.D.

The study author who explained that new treatments for stroke may come from multi-target neuroprotective agents, which could lead to important advancements in reducing or preventing disability after a stroke.

American Stroke Association

The organization that hosted the International Stroke Conference 2026 where the loberamisal trial results were presented.

Got photos? Submit your photos here. ›

What they’re saying

“New treatments for stroke may come from multi-target neuroprotective agents, which could lead to important advancements in reducing or preventing disability after a stroke.”

— Shuya Li, M.D.

What’s next

Researchers plan to conduct larger, more diverse trials to confirm these initial findings. They also aim to investigate the potential benefits of combining loberamisal with existing stroke treatments, such as alteplase, and thrombectomy.

The takeaway

This trial suggests a potential shift in stroke care, moving beyond simply restoring blood flow to actively protecting brain cells from damage. The promising results with loberamisal highlight the evolving landscape of stroke treatment and the renewed interest in neuroprotection as a way to improve outcomes for stroke patients.